Clinical trial
A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study of Safety, Tolerability and Evidence of Activity of Intravitreal APL-2 Therapy in Patients With Geographic Atrophy (GA)
NCT02503332 is registered in ClinicalTrials.gov with Apellis Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study of Safety, Tolerability and Evidence of Activity of Intravitreal APL-2 Therapy in Patients With Geographic Atrophy (GA)
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 24, 2015
- Completion date
- January 17, 2018
- Enrollment
- 246 (actual)
- Sites
- 46
Conditions
As the registry lists them; a condition with its own page is linked.